Journal
ACTA DERMATO-VENEREOLOGICA
Volume 98, Issue 9, Pages 829-834Publisher
ACTA DERMATO-VENEREOLOGICA
DOI: 10.2340/00015555-2989
Keywords
psoriasis; secukinumab; hepatitis B; hepatitis C; interleukin-17A inhibitor; biologics
Categories
Funding
- National Taiwan University Hospital, Hsin-Chu branch [HCH 106-HCH055, 107-HCH057]
- Chang Gung Memorial Hospital [CMRPG2F0332]
- Basic Research Award, Asia-Pacific La Roche-Posay Foundation
Ask authors/readers for more resources
Safety data for secukinumab in patients with psoriasis and viral hepatitis are lacking. The aim of this study is to investigate the risk of reactivation of hepatitis B virus (HBV)/hepatitis C virus (HCV) in patients with psoriasis who are receiving secukinumab therapy. This multicentre study screened 284 patients with psoriasis with available HBV and HCV serological data and 63 patients with concurrent HBV/HCV infection were enrolled. In the absence of antiviral prophylaxis, 7 of 46 (15.2%) patients with HBV exhibited HBV reactivation during secukinumab therapy. The risk of reactivation was significantly higher in HBsAg-positive patients, compared with HBsAg-negative/HBcAb-positive patients (24.0% vs. 4.17%, p = 0.047). One of 14 (7.1%) HCV patients showed enhanced replication of HCV with hepatitis. No virus reactivation occurred in patients receiving antiviral prophylaxis. HBsAg-positive and HBsAg-negative/HBcAb-positive psoriasis patients can develop virus reactivation during secukinumab therapy, thus necessitating close monitoring of viral load and considering an antiviral prophylaxis for all HBsAg-positive patients with psoriasis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available